ARE NEUROPHYSIOLOGICAL PARAMETERS AN OBJECTIVE MEASURE OF DISEASE STATUS AND PROGRESSION IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS?

被引：0
作者：
Witherick, J.
Kane, N.
Butler, S.
Walsh, P.
Blake, K.
Faulkner, H.
Burrows, J.
Inglis, K.
Cottrell, D.
机构：
[1] N Bristol NHS Trust, Frenchay Hosp, Dept Neurol, Bristol, Avon, England
[2] N Bristol NHS Trust, Frenchay Hosp, Dept Neurophysiol, Bristol, Avon, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2012年 / 83卷 / 03期
关键词：
D O I：
10.1136/jnnp-2011-301993.194
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis
    Cadavid, Diego
    Tang, Yongqiang
    O'Neill, Gilmore
    REVISTA DE NEUROLOGIA, 2010, 51 (06) : 321 - 329
  • [42] Spinal cord atrophy as a primary outcome measure in primary progressive multiple sclerosis neuroprotective trials
    Cawley, N.
    Abdel-Aziz, K.
    Schneider, T.
    Altmann, D.
    Wheeler-Kingshott, C. A. M.
    Miller, D. H.
    Thompson, A. J.
    Ciccarelli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 189 - 190
  • [43] A multiple sclerosis disease progression measure based on rate of cumulative disability
    Manouchehrinia, A.
    Hillert, J.
    Ramanujam, R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 79 - 80
  • [44] Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis
    Letizia Leocani
    Arturo Nuara
    Elise Houdayer
    Irene Schiavetti
    Ubaldo Del Carro
    Stefano Amadio
    Laura Straffi
    Paolo Rossi
    Vittorio Martinelli
    Carlos Vila
    Maria Pia Sormani
    Giancarlo Comi
    Journal of Neurology, 2015, 262 : 2520 - 2527
  • [45] The lymphocyte subpopulation in patients with primary progressive multiple sclerosis and secondary progressive multiple sclerosis
    Belniak, Ewa
    Bojarska-Junak, Agnieszka
    Bartosik-Psujek, Halina
    Mitosek-Szewezyk, Krystyna
    Kulka, Malgorzata
    Stelmasiak, Zbigniew
    Rolinski, Jacek
    MULTIPLE SCLEROSIS, 2008, 14 : S116 - S116
  • [46] Ocrelizumab for primary progressive multiple sclerosis
    Adler, Ai
    Knight, H.
    LANCET NEUROLOGY, 2019, 18 (09) : 816 - 817
  • [47] The pathology of primary progressive multiple sclerosis
    Lucchinetti, C
    Bruck, W
    MULTIPLE SCLEROSIS JOURNAL, 2004, 10 : S23 - S30
  • [48] Ocrelizumab for primary progressive multiple sclerosis
    Montalban X
    Hauser SL
    Kappos L
    中华物理医学与康复杂志, 2017, (03) : 174 - 174
  • [49] Primary progressive multiple sclerosis in Brazil
    Vasconcelos, CCF
    Alvarenga, M
    Papais-Alvarenga, R
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S218 - S219
  • [50] Primary and secondary progressive multiple sclerosis
    Vukusic, S
    Confavreux, C
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) : 153 - 155
12345